Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions


This paper has been written within the industry working group estimands in oncology, which is both, a European special interest group “Estimands in oncology”, sponsored by PSI and European Federation of Statisticians in the Pharmaceutical Industry (EFSPI)} and a scientific working group of the biopharmaceutical section of the American Statistical Association. Details are available on www.oncoestimand.org.